Skip to main content

Table 4 Changes of alveolar surfactant protein A, B, C of serum

From: Can apneic oxygen insufflation become a novel lung protective ventilation strategy? A randomized, controlled, blinded, single center clinical trial

 

T1

T2

T3

SP-A

(ng/ml)

group C

0.29[0.11–0.42]

0.38[0.22–0.52]a

0.45[0.34–0.61]ab

group T

0.31[0.24–0.37]

0.38[0.31–0.47]a

0.39[0.32–0.47]ac

SP-B (ng/ml)

group C

4.19[3.05–6.03]

5.85[5.20–6.86]a

6.86[5.69–9.191]a

group T

4.28[4.01–4.87]

4.80[4.63–5.39]ac

5.49[5.10–6.64]abc

SP-C

(ng/ml)

group C

0.37[0.31–0.48]

0.66[0.45–0.80]a

1.06[0.59–1.73]ab

group T

0.36[0.19–0.49]

0.47[0.32–0.61]ac

0.76[0.28–1.05]abc

  1. Changes of alveolar surfactant protein A, B, C of serum at each time point, and the difference was statistically significant. Compared with those at T1,a P < 0.05;Compared with those at T2, b P < 0.05;Compared with those of group C, c P < 0.05.Values are median [25e-75e percentile], One-way ANOVA (and nonparametric) was used for intra-group comparison, and Mann Whitney test was used in the comparison between groups,one-tailed P values